METTL14 and IGF2BPs are involved in the stabilization of m6A-modified HNF3γ mRNA, which promotes cell apoptosis, thereby sensitizing HCC cells to sorafenib treatment [102]. The gene discussed is METTL14; the disease is hepatocellular carcinoma.